208 related articles for article (PubMed ID: 11395856)
1. Effects of epoetin alfa on the central nervous system.
Cerami A; Brines ML; Ghezzi P; Cerami CJ
Semin Oncol; 2001 Apr; 28(2 Suppl 8):66-70. PubMed ID: 11395856
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotective properties of epoetin alfa.
Cerami A; Brines M; Ghezzi P; Cerami C; Itri LM
Nephrol Dial Transplant; 2002; 17 Suppl 1():8-12. PubMed ID: 11812906
[TBL] [Abstract][Full Text] [Related]
3. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.
Brines ML; Ghezzi P; Keenan S; Agnello D; de Lanerolle NC; Cerami C; Itri LM; Cerami A
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10526-31. PubMed ID: 10984541
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system frontiers for the use of erythropoietin.
Olsen NV
Clin Infect Dis; 2003; 37 Suppl 4():S323-30. PubMed ID: 14582001
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietic agents as neurotherapeutic agents: what barriers exist?
Jumbe NL
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):91-107. PubMed ID: 12380959
[TBL] [Abstract][Full Text] [Related]
6. Beyond erythropoiesis: novel applications for recombinant human erythropoietin.
Cerami A
Semin Hematol; 2001 Jul; 38(3 Suppl 7):33-9. PubMed ID: 11523026
[TBL] [Abstract][Full Text] [Related]
7. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage.
Juul S
Acta Paediatr Suppl; 2002; 91(438):36-42. PubMed ID: 12477263
[TBL] [Abstract][Full Text] [Related]
8. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications.
Weiss MJ
Oncologist; 2003; 8 Suppl 3():18-29. PubMed ID: 14671225
[TBL] [Abstract][Full Text] [Related]
9. Beyond anaemia management: evolving role of erythropoietin therapy in neurological disorders, multiple myeloma and tumour hypoxia models.
Boogaerts M; Mittelman M; Vaupel P
Oncology; 2005; 69 Suppl 2():22-30. PubMed ID: 16244507
[TBL] [Abstract][Full Text] [Related]
10. Erythropoietin delivered via intra-arterial infusion reduces endoplasmic reticulum stress in brain microvessels of rats following cerebral ischemia and reperfusion.
Zhao H; Wang R; Wu X; Liang J; Qi Z; Liu X; Min L; Ji X; Luo Y
J Neuroimmune Pharmacol; 2015 Mar; 10(1):153-61. PubMed ID: 25626440
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin (epoetin) as a protective factor for the brain.
Malhotra S; Nijhawan S; Rosenbaum DM
Curr Atheroscler Rep; 2004 Jul; 6(4):301-6. PubMed ID: 15191705
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview.
Bieber E
J Reprod Med; 2001 May; 46(5 Suppl):521-30. PubMed ID: 11396386
[TBL] [Abstract][Full Text] [Related]
13. The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.
Yoo SJ; Cho B; Lee D; Son G; Lee YB; Soo Han H; Kim E; Moon C; Moon C
Cell Death Dis; 2017 Aug; 8(8):e3003. PubMed ID: 28817120
[TBL] [Abstract][Full Text] [Related]
14. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia.
Wang Y; Zhang ZG; Rhodes K; Renzi M; Zhang RL; Kapke A; Lu M; Pool C; Heavner G; Chopp M
Br J Pharmacol; 2007 Aug; 151(8):1377-84. PubMed ID: 17603558
[TBL] [Abstract][Full Text] [Related]
15. The erythropoietin receptor and its expression in tumor cells and other tissues.
Farrell F; Lee A
Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
[TBL] [Abstract][Full Text] [Related]
16. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties.
Storring PL; Tiplady RJ; Gaines Das RE; Stenning BE; Lamikanra A; Rafferty B; Lee J
Br J Haematol; 1998 Jan; 100(1):79-89. PubMed ID: 9450795
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications.
Leyland-Jones B; O'shaughnessy JA
Semin Oncol; 2003 Oct; 30(5 Suppl 16):174-84. PubMed ID: 14613039
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective effect of erythropoietin and darbepoetin alfa after experimental intracerebral hemorrhage.
Grasso G; Graziano F; Sfacteria A; Carletti F; Meli F; Maugeri R; Passalacqua M; Certo F; Fazio M; Buemi M; Iacopino DG
Neurosurgery; 2009 Oct; 65(4):763-9; discussion 769-70. PubMed ID: 19834382
[TBL] [Abstract][Full Text] [Related]
19. Circulating damage marker profiles support a neuroprotective effect of erythropoietin in ischemic stroke patients.
Ehrenreich H; Kästner A; Weissenborn K; Streeter J; Sperling S; Wang KK; Worthmann H; Hayes RL; von Ahsen N; Kastrup A; Jeromin A; Herrmann M
Mol Med; 2011; 17(11-12):1306-10. PubMed ID: 21912808
[TBL] [Abstract][Full Text] [Related]
20. Activity increase in EpoR and Epo expression by intranasal recombinant human erythropoietin (rhEpo) administration in ischemic hippocampi of adult rats.
Castañeda-Arellano R; Feria-Velasco AI; Rivera-Cervantes MC
Neurosci Lett; 2014 Nov; 583():16-20. PubMed ID: 25219375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
